NasdaqCM - Nasdaq Real Time Price • USD
OKYO Pharma Limited (OKYO)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 6:54 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Gary S. Jacob Ph.D. | CEO & Executive Director | 650k | -- | 1947 |
Mr. Michael Paul Beck | Founder | -- | -- | 1957 |
Ms. Keeren Shah | Chief Financial Officer | -- | -- | 1976 |
Dr. William A. Clementi Ph.D., Pharm.D. | Chief Operating Officer | -- | -- | -- |
Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer | -- | -- | 1959 |
OKYO Pharma Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 8
Description
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
Corporate Governance
OKYO Pharma Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 09, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 04, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 22, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 21, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 20, 20246-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Upcoming Events Information Not Available
Related Tickers
688222.SS HitGen Inc.
12.90
+5.31%
ELVAF Evolva Holding SA
1.1000
0.00%
DRMAW Dermata Therapeutics, Inc.
0.0092
0.00%
IVBXF Innovent Biologics, Inc.
4.8900
+12.41%
AX9.F Akebia Therapeutics, Inc.
1.2410
-3.80%
RDTCF Rapid Dose Therapeutics Corp.
0.0151
0.00%
HVO.IR hVIVO plc
0.3200
0.00%
ICCC ImmuCell Corporation
5.04
-0.20%
BLT.NZ BLIS Technologies Limited
0.0170
0.00%
CMRA Comera Life Sciences Holdings, Inc.
0.0410
0.00%